Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Brilacidin + BeaMed = CON
B-UC is on the shelf, as stated by Leo.
Leo’s clinical trial milestones in 2022:
1.
I thought you answered yourself already when you said BPs are so threatened by Brilacidin's potential they could lose billions of revenue because B can replace their current drugs.
Let’s say BP X has a drug Y with $1B in revenue. Let’s also say Brilacidin has the potential to dominate drug Y with $2B in revenue. If you are the CEO, wouldn’t you want to acquire B and make $1B more in revenue?
The only way BP X could avoid losing billions of revenue in drug Y is to prevent their competitors from acquiring B. There should be a bidding war if B truly has the potential to dominate drug Y. The fact that no BP wants to acquire B in almost 10 years should tell you all about its potential.
What does it tell you about the “breakthrough” laser technology if the only offer was from a penny stock?
If you are the owner of BeaMedical and truly believe you have a breakthrough product, wouldn’t you want to either go public or make a bigger deal with BP instead of giving 40% to IPIX?
The FDA didn't put any trials on hold. They granted QIDP for ABSSSI and Fast Track for OM. I don't recall you complaining about the FDA manipulating the trials when the P2b and P2 result came out. Leo hasn't requested a meeting for OM P3 despite many promises, how is that the FDA's fault? If Leo truly believes your theory, he could've run the P3 trial in Europe years ago since he has an "subsidiary" there.
BP #1 - You can have the next Humira. B’s potential revenue is too massive for us.
BP #2 - No you can have it. As a competitor I want you to make more money.
BP #1 - Let’s lowball IPIX a couple of million so we can lose billions of revenue every year.
BP #2 - Agreed!
Pete, the writing is on the wall long time ago. Hopefully you can see it before B disappears from the IPIX website.
Telling potential buyers you don’t have money is the best negotiation strategy to get the most out of K. Removing all traces of K on the IPIX website further increases Leo’s leverage.
The latest 10-Q should tell you where Leo's priority is.
- All clinical developments of B & K - paused
- Leo's salary - not paused
Sure you can argue that his salary is not Leo's top priority, but can you argue that the clinical developments of B & K has a higher priority than his salary?
Here's Leo's latest math on B-OM:
By "evidence" I assume you mean the in vitro data that Leo has been hyping since 2020?
100% agree. Leo pumps the stock so KIPS Bay can dump it.
B and K are on the shelf so Leo did abandon their development. Shareholders have waited many years for Leo to make a deal with significant non-dilutive funding. Not only Leo failed to do that since B-ABSSSI completed Phase 2b in 2014, he spent $4M on Squalus while claiming not having enough money to complete K toxicology studies. So yes, he'll ask for more authorized shares so he can dilute shareholders like you into oblivion.
If you are Squalus who truly has a promising technology/product, why would you give up 40% of the company to IPIX? Why not give the equity to BPs who have the resources to develop and market it?
IMO Leo knows it takes money (shareholder's) to make money (for him). Shareholders are more likely to authorize more outstanding shares with this deal. That should guarantee him another decade of salary.
Today's news did not excite the market either. Minority stake could be 1%. Knowing Leo if it's 49% he would have hyped the PR.
Maybe Squalus is laser-focused (no pun intended) on the science like Leo so they don't have time for their "website".
According to my sources, the new hire works in the sales department at the Irish subsidiary. No signing bonus, minimum wage, salary is commission-based.
It's easy to make stuff up.
Actually it took less than one minute. Go to the main page and type "transformation" in the search box on the upper right corner. The first result is that PR.
The word "transformation" seems to be a favorite among Leo and his shareholders. In 2013 he said:
Pete, the short interest was 466,169 shares as of 5/13. That's 0.1% of the total OS.
https://otce.finra.org/otce/equityShortInterest
The latest fails-to-deliver number was 5,290 shares as of 5/12.
20220512|45782D100|IPIX|5290|INNOVATION PHARMACEU|0.03
https://www.sec.gov/data/foiadocsfailsdatahtm
It takes two to make a deal. Your post sounds like Leo had plenty of offers to choose from and he's waiting for the best one. In the past he hyped about a term sheet or hiring Locust Walk. Now he stopped basically everything except his paychecks.
Waiting for a deal -> BP's money
Waiting to complete toxicology studies -> IPIX's money
Big difference.
Thanks for showing another example of promising anti-cancer drugs being acquired by BPs. Waiting for a deal is different than being stuck in toxicology studies. Leo has the money to complete it but chose not to. That should tell you how "valuable" K is.
"First Time In History": Cancer Vanishes For Every Patient In Drug Trial
Welcome back! You would expect Leo to PR the new hire if the position was important. Your previous post from 4 years ago said:
Mack, the stock is down 99% from its all-time high and there's negativity around it? Just wondering why you think a lot is going on behind the scene since Leo put B on the shelf.
Oral Mucositis Market 2017
Key Players
- Celleutix Corporation (USA)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134146432
I shared this Pfizer-Arena example before. The deal (and many others) refutes the claim here that BPs are afraid new drugs will threaten their profits so they are working together to bankrupt the smaller companies.
IPIX had 317 fails-to-deliver shares in the second half of March 2022.
20220322|45782D100|IPIX|317|INNOVATION PHARMACEU|0.04
https://www.sec.gov/data/foiadocsfailsdatahtm
The April data does not show IPIX has any fails-to-deliver shares.
If you have data backed by creditable sources showing millions of air shares in IPIX, please share it.
I used to post similar market reports on B-ABSSSI and B-OM years ago. Here's an example in 2017 on B-OM.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134146432
Nothing happened since...
I bet BPs said we can't do a deal because some anonymous posters claimed there are millions of fake shares without proof, no matter how many billions of revenue B could generate.
This is the same poster who also said:
B-OM Phase 3 went from planning to delayed.
Instead of speculating, why do you think Leo didn't disclose the dosage for the COVID trial like he did for the ABSSSI trial? Shareholders deserve to know this information, but common sense says Leo don't want you to know because it's not good.
Exactly, how would the Edison Group know? That's some of us' point - to take the report with a grain of salt.
PJ, I see you like to say "anything is possible" a lot. I hope your investment is not based on it. You should consider how likely is something using historical data.
The average temperature of the South Pole is -56F. Will it be +56F this year? Yes anything is possible, but highly unlikely.
Mack, if you are the CEO of Basilea, will you risk creating competitions for B by announcing your interest before a deal is done or will you negotiate quietly behind the scenes and make it public after a deal is done?
Basilea is a small cap pharma with a $395M market cap and $6.53M in net income last quarter. Not sure how much they can offer IPIX but that's another discussion.
Your claim could be true if there has been no deals made in the past 8 years, but BPs have been making deals constantly to replenish their pipeline and revenue. Also B-ABSSSI has nothing to do with COVID.
The Phase 2b result was almost 8 years ago. Why there's no partner if it's so promising?
https://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin